Bernhard Kirschbaum
Director/Board Member at REDX PHARMA PLC
Profile
Bernhard Kirschbaum is currently serving as the Chairman-Supervisory Board at Protagen AG, Chairman at OMEICOS Therapeutics GmbH, Independent Non-Executive Director at Redx Pharma Plc, Director at BioMedx Group, Inc., Scientific Advisor at FutuRx Ltd., and Member-Supervisory Board at BioMed X GmbH.
He started his position as Member-Supervisory Board at Amarna Therapeutics BV in 2019.
Previously, Dr. Kirschbaum worked as a Research Director at Merck Serono SA from 2005 to 2012.
He also held positions as a Director at Enlivex Therapeutics Ltd.
and KAHR Medical Ltd., as well as an Independent Director at Enlivex Therapeutics Ltd.
He has experience as a Principal at Institut Pasteur and The Rockefeller University.
Additionally, he served as the Vice President-Discovery Research at Sanofi-Aventis Deutschland GmbH.
Dr. Kirschbaum obtained his doctorate degree from Universität Konstanz in 1989.
Bernhard Kirschbaum active positions
Companies | Position | Start |
---|---|---|
REDX PHARMA PLC | Director/Board Member | 31/12/2015 |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Chairman | - |
BioMedx Group, Inc.
BioMedx Group, Inc. Medical SpecialtiesHealth Technology BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD. | Director/Board Member | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Director/Board Member | 15/10/2019 |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | Director/Board Member | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Consultant / Advisor | - |
Former positions of Bernhard Kirschbaum
Companies | Position | End |
---|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
ENLIVEX THERAPEUTICS LTD. | Director/Board Member | - |
░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░ ░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Bernhard Kirschbaum
Universität Konstanz | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
REDX PHARMA PLC | Health Technology |
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private companies | 11 |
---|---|
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Health Technology |
Protagen AG
Protagen AG BiotechnologyHealth Technology Protagen AG specializes in the development of novel diagnostic and companion diagnostic tests. Its products and services include GMP analyses, protein identification and analyses, proteome studies, UNIchip, clone and array, Bio-IT, Modiro as well as ProteinScape and Solver. The company was founded by Stefan Müllner, Helmut E. Meyer, Petra Weingarten and Martin Blüggel in 1997 and is headquartered in Dortmund, Germany. | Health Technology |
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Health Technology |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Miscellaneous |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
BioMedx Group, Inc.
BioMedx Group, Inc. Medical SpecialtiesHealth Technology BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD. | Health Technology |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | Commercial Services |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Finance |
- Stock Market
- Insiders
- Bernhard Kirschbaum